Dihydrotestosterone regulating apolipoprotein M expression mediates via protein kinase C in HepG2 cells
详细信息 查看全文
- 作者：Ye Yi-zhou (1)
Cao Bing (2)
Li Ming-qiu (3)
Wang Wei (4)
Wang Ru-xing (3)
Rui Jun (3)
Wei Liu-yan (3)
Jing Zhao-hui (3)
Ji Yong (3)
Jiao Guo qing (3)
Zou Jian (3) - 关键词：Androgen ; DHT ; ApoM ; PKC
- 刊名：Lipids in Health and Disease
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：11
- 期：1
- 全文大小：461KB
- 参考文献：1. Somboonporn W: Testosterone therapy for postmenopausal women: efficacy and safety. / Semin Reprod Med 2006,24(2):115-24. CrossRef
2. Shabsigh R, Katz M, Yan G, Makhsida N: Cardiovascular issues in hypogonadism and testosterone therapy. / Am J Cardiol 2005,96(12B):67M-72M. CrossRef
3. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS: Testosterone as a protective factor against atherosclerosis—immunomodulation and influence upon plaque development and stability. / J Endocrinol 2003,178(3):373-80. CrossRef
4. Xu N, Dahlb?ck B: A novel human apolipoprotein (apoM). / J Biol Chem 1999,274(44):31286-1290. CrossRef
5. Luo G, Zhang X, Nilsson-Ehle P, Xu N: Apolipoprotein M. / Lipids Health Dis 2004, 3:21. CrossRef
6. Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N: Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. / Acta Histochem 2003,105(1):67-2. CrossRef
7. Zhang XY, Jiao GQ, Hurtig M, Dong X, Zheng L, Luo GH, Nilsson-Ehle P, Ye Q, Xu N: Expression pattern of apolipoprotein M during mouse and human embryogenesis. / Acta Histochem 2004,106(2):123-28. CrossRef
8. Wolfrum C, Poy MN, Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. / Nat Med 2005,11(4):418-22. CrossRef
9. Xu N, Nilsson-Ehle P, Hurtig M, Ahrén B: Both leptin and leptin receptor are essential for apolipoprotein M expression in vivo. / Biochem Biophys Res Commun 2004,321(4):916-21. CrossRef
10. Xu N, Nilsson-Ehle P, Ahrén B: Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. / J Nutr Biochem 2004,15(10):579-82. CrossRef
11. Xu N, Ekstrom U, Nilsson-Ehle P: Acth decreases the expression and secretion of apolipoprotein b in hepg2 cell cultures. / J Biol Chem 2001,276(42):38680-8684. CrossRef
12. Xu N, Zhang XY, Dong X, Ekstr?m U, Ye Q, Nilsson-Ehle P: Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells. / Biochem Biophys Res Commun 2002,292(4):944-50. CrossRef
13. Xu N, Hurtig M, Zhang XY, Ye Q, Nilsson-Ehle P: Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. / Biochim Biophys Acta 2004,1683(1):33-7. CrossRef
14. Xu N, Hurtig M, Ekstr?m U, Nilsson-Ehle P: Adrenocorticotrophic hormone retarded metabolism of low-density lipoprotein in rats, Scand. / J Clin Lab Invest 2004,64(3):217-22. CrossRef
15. Berg G, Schreier L, Geloso G, Otero P, Nagelberg A, Levalle O: Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men. / Horm Metab Res 2002,34(2):87-2. CrossRef
16. Dickerman RD, McConathy WJ, Zachariah NY: Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. / J Cardiovasc Risk 1997,4(5-):363-66. CrossRef
17. Eckardstein A, Wu FC: Testosterone and atherosclerosis. / Growth Horm IGF Res 2003,13(Suppl A):S72-S84. CrossRef
18. Grundy SM, Vega GL, Otvos JD, Rainwater DL, Cohen JC: Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. / J Lipid Res 1999,40(2):229-34.
19. De Pergola G: The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. / Int J Obes Relat Metab Disord 2000,24(Suppl 2):S59-S63. CrossRef
20. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlb?ck B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. / J Lipid Res 2006,47(8):1833-843. CrossRef
21. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E: Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. / Clin Chem 1998,44(8 Pt 1):1641-649.
22. Nantermet P, Harada S, Liu Y, Cheng S, Johnson C, Yu Y, Kimme D, Holder D, Hodor P, Phillips R, Ray WJ: Gene Expression Analyses in Cynomolgus Monkeys Provides Mechanistic Insight into High-Density Lipoprotein-Cholesterol Reduction by Androgens in Primates. / Endocrinology 2008,149(4):1551-561. CrossRef
23. Meroni SB, Pellizzari EH, Canepa DF, Cigorraga SB: Possible involvement of ceramide in the regulation of rat Leydig cell function. / J Steroid Biochem Mol Biol 2000,75(4-):307-13. CrossRef
24. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. / Science 1996,274(5294):1855-859. CrossRef
25. Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M: Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. / J Cell Biochem 2004,91(4):840-51. CrossRef
26. Nieuwenhuis B, Luth A, Chun J, Huwiler A, Pfeilschifter J, Schafer-Korting M, Kleuser B: Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. / J Mol Med 2009,87(6):645-57. CrossRef
27. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. / J Cell Biol 2006,173(2):301-10. CrossRef
28. Aoki S, Yatomi Y, Ohta M, Osada M, Kazama F, Satoh K, Nakahara K, Ozaki Y: Sphingosine 1-phosphate-related metabolism in the blood vessel. / J Biochem 2005,138(1):47-5. CrossRef
29. Argraves KM, Argraves WS: HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. / J Lipid Res 2007,48(11):2325-333. CrossRef
30. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im DS, Sato K, Murakami M, Okajima F: Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. / J Biol Chem 2006,281(49):37457-7467. CrossRef
31. Nofer JR, van der Giet M, T?lle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, G?decke A, Ishii I, Kleuser B, Sch?fers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B: DL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. / J Clin Invest 2004,113(4):569-81.
32. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM: Argraves WSHigh density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. / J Biol Chem 2008,283(36):25074-5081. CrossRef
33. Christoffersen C, Ahnstr?m J, Axler O, Christensen EI, Dahlb?ck B, Nielsen LB: The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. / J Biol Chem 2008,283(27):18765-8772. CrossRef
34. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlb?ck B, Nielsen LB: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. / J Biol Chem 2008,283(4):1839-847. CrossRef
35. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstr?m J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlb?ck B: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. / Proc Natl Acad Sci USA 2011,108(23):9613-618. CrossRef
36. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B: Regulation of androgen action. / Vitam Horm 1999, 55:309-52. CrossRef
37. Heinlein CA, Chang C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. / Mol Endocrino 2002,16(10):2181-187. CrossRef
38. Boonyaratanakornkit V, Edwards DP: Receptor mechanisms mediating non-genomic actions of sex steroids. / Semin Reprod Med 2007,25(3):139-53. CrossRef
39. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F: Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. / EMBO J 2000,19(20):5406-417. CrossRef
40. Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. / Cell 2001,104(5):719-30.
41. Guo Z, Benten WP, Krucken J, Wunderlich F: Nongenomic testosterone calcium signaling Genotropic actions in androgen receptor-free macrophages. / J Biol Chem 2002,277(33):29600-9607. CrossRef
42. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. / J Biol Chem 2003,278(44):42992-3000. CrossRef
43. Nguyen TV, Yao M, Pike CJ: Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. / J Neurochem 2005,94(6):1639-651. CrossRef
44. Sun YH, Gao X, Tang YJ, Xu CL, Wang LH: Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. / J Androl 2006,27(5):671-78. CrossRef
45. Zhang Y, Chen CJ, Yang QL, Cheng LQ, Wang H, Huang LZ: Effect of interfering hepatocyte nuclear factor-1 alfa in HepG2 on the expressions of apoM, apoA-I and the correlative key enzyme of cholesterol metabolism. / Zhonghua Gan Zang Bing Za Zhi 2011,19(2):121-26.
46. Mosialou I, Zannis VI, Kardassis D: Regulation of human apolipoprotein M gene expression by orphan and ligand-dependent nuclear receptors. / J Biol Chem 2010,285(40):30719-0730. CrossRef
47. Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N: Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. / Biochem Biophys Res Commun 2008,371(1):114-17. CrossRef
48. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW: Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. / Cell Tissue Res 2009,335(1):165-89. CrossRef
49. Yanagawa T, Taniguchi A, Fukushima M, Nakai Y, Nagasaka S, Ohgushi M, Matsumoto K, Kuroe A, Ohya M, Seino Y: Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. / Diabetes Res Clin Pract 2007,75(1):2-. CrossRef
50. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, Wallace AM, Sattar N: Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. / Atherosclerosis 2007,191(2):418-26. CrossRef
51. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. / J Clin Endocrinol Metab 2004,89(8):3872-878. CrossRef
52. Luo G, Hurtig M, Zhang X, Nilsson-Ehle P, Xu N: Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. / Biochim Biophys Acta 2005,1734(2):198-02. CrossRef
53. Xu N, Ahrén B, Jiang J, Nilsson-Ehle P: Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. / Biochim Biophys Acta 2006,1761(2):256-60. CrossRef - 作者单位：Ye Yi-zhou (1)
Cao Bing (2)
Li Ming-qiu (3)
Wang Wei (4)
Wang Ru-xing (3)
Rui Jun (3)
Wei Liu-yan (3)
Jing Zhao-hui (3)
Ji Yong (3)
Jiao Guo qing (3)
Zou Jian (3)
1. Department of Cardiovascular Surgery, Affiliated Shanghai 1st People’s Hospital, Shanghai Jiaotong University, Shanghai, 210008, People’s Republic of China
2. Department of Cardiothoracic Surgery, Affiliated Taixing People’s Hospital, Yangzhou Medical University, Taixing, 225400, People’s Republic of China
3. Department of Cardiovascular Surgery, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Qingyang Road 299, Wuxi City, Jiangsu Province, 214023, China
4. Department of Cardiovascular Surgery, National Center for Cardiovascular Disease, Beijing, 200000, People’s Republic of China
文摘
Background Administration of androgens decreases plasma concentrations of high-density lipid cholesterol (HDL-C). However, the mechanisms by which androgens mediate lipid metabolism remain unknown. This present study used HepG2 cell cultures and ovariectomized C57BL/6 J mice to determine whether apolipoprotein M (ApoM), a constituent of HDL, was affected by dihydrotestosterone (DHT). Methods HepG2 cells were cultured in the presence of either DHT, agonist of protein kinase C (PKC), phorbol-12-myristate-13-acetate (PMA), blocker of androgen receptor flutamide together with different concentrations of DHT, or DHT together with staurosporine at different concentrations for 24 hrs. Ovariectomized C57BL/6 J mice were treated with DHT or vehicle for 7d or 14d and the levels of plasma ApoM and livers ApoM mRNA were measured. The mRNA levels of ApoM, ApoAI were determined by real-time RT-PCR. ApoM and ApoAI were determined by western blotting analysis. Results Addition of DHT to cell culture medium selectively down-regulated ApoM mRNA expression and ApoM secretion in a dose-dependent manner. At 10 nM DHT, the ApoM mRNA levels were about 20% lower than in untreated cells and about 40% lower at 1000 nM DHT than in the control cells. The secretion of ApoM into the medium was reduced to a similar extent. The inhibitory effect of DHT on ApoM secretion was not blocked by the classical androgen receptor blocker flutamide but by an antagonist of PKC, Staurosporine. Agonist of PKC, PMA, also reduced ApoM. At 0.5 μM PMA, the ApoM mRNA levels and the secretion of ApoM into the medium were about 30% lower than in the control cells. The mRNA expression levels and secretion of another HDL-associated apolipoprotein AI (ApoAI) were not affected by DHT. The levels of plasma ApoM and liver ApoM mRNA of DHT-treated C57BL/6 J mice were lower than those of vehicle-treated mice. Conclusions DHT directly and selectively down-regulated the level of ApoM mRNA and the secretion of ApoM by protein kinase C but independently of the classical androgen receptor.